14 completed, 4 withdrawn, 3 terminated, 1 suspended. 11 Phase 2, 9 Phase 1, 2 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 6, Withdrawn 3, Terminated 2 |
| Phase 1 | 9 | Completed 6, Suspended 1, Terminated 1, Withdrawn 1 |
| Early Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Giant Cell Glioblastoma: new trials by email Literature Review of Giant Cell Glioblastoma trials Research Report on Giant Cell Glioblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status) S-Gboxin - Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 1 | Suspended | Petrov, Andrey | 10 | 2026-05-20 | 2026-06-03 |
| HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma Biological G207 - Neoplasms, High Grade Glioma | Phase 2 | Withdrawn | Pediatric Brain Tumor Consortium | 2025-09-01 | 2026-02-10 | |
| CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type CYNK-001 systemic and Intra cavity administration - Astrocytoma, Grade IV, Glioblastoma | Phase 1 / Phase 2 | Withdrawn | Celularity Incorporated | 2021-09-01 | 2026-06-08 | |
| Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM CYNK001-IV, CYNK001-IT - Astrocytoma, Grade IV, Giant Cell Glioblastoma | Phase 1 | Terminated | Celularity Incorporated | 3 | 2020-10-01 | 2022-08-10 |
| Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma autologous dendritic cells pulsed with tumor lysate antigen Vaccine, Laboratory Biomarker Analysis, Nivolumab - Giant Cell Glioblastoma, Gliosarcoma | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2019-12-01 | 2020-07-24 | |
| Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma LB-100 - Astrocytoma, Grades II, III and IV, Glioblastoma Multiforme | Phase 2 | Completed | National Cancer Institute (NCI) | 7 | 2019-01-09 | 2023-11-22 |
| Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma Radiation - Astrocytoma, Grade IV, Giant Cell Glioblastoma | Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2016-06-15 | 2025-12-31 |
| DC Migration Study for Newly-Diagnosed GBM Unpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs - Glioblastoma, Astrocytoma, Grade IV | Phase 2 | Completed | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | 64 | 2015-10-12 | 2023-06-08 |
| Vaccine Therapy in Treating Patients With Recurrent Glioblastoma Laboratory Biomarker Analysis, Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine - Giant Cell Glioblastoma, Recurrent Glioblastoma | Early Phase 1 | Completed | Mayo Clinic | 20 | 2013-11-27 | 2023-06-28 |
| Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Laboratory Biomarker Analysis, Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine, Temozolomide - Giant Cell Glioblastoma, Glioblastoma | Early Phase 1 | Completed | Mayo Clinic | 21 | 2013-11-11 | 2023-11-18 |
| p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors azurin-derived cell-penetrating peptide p28 - Teratoid Tumor, Atypical, Choroid Plexus Neoplasms | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 18 | 2013-08-01 | 2017-08-07 |
| Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors imetelstat sodium - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 2 | Terminated | Pediatric Brain Tumor Consortium | 43 | 2013-03-01 | 2018-07-20 |
| Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Laboratory Biomarker Analysis, Montanide ISA-51/Survivin Peptide Vaccine, Sargramostim - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 9 | 2012-09-05 | 2017-02-27 |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study - Giant Cell Glioblastoma, Glioblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 137 | 2012-06-04 | 2022-07-21 |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis - Anaplastic Astrocytoma, Brain Stem Glioma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 66 | 2012-02-01 | 2019-08-13 |
| A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH - Glioblastoma, Small Cell Glioblastoma | Phase 2 | Completed | Celldex Therapeutics | 127 | 2011-12-01 | 2020-02-17 |
| Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH - Glioblastoma, Small Cell Glioblastoma | Phase 3 | Completed | Celldex Therapeutics | 745 | 2011-11-01 | 2018-01-16 |
| Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | City of Hope Medical Center | 6 | 2011-03-22 | 2026-10-19 |
| Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma bevacizumab, temozolomide, laboratory biomarker analysis - Giant Cell Glioblastoma, Glioblastoma | Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 50 | 2010-04-28 | 2024-09-19 |
| Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma XL184, temozolomide, Radiation Therapy - Glioblastoma, Giant Cell Glioblastoma | Phase 1 | Completed | Exelixis | 26 | 2009-09-01 | 2014-09-22 |
Showing 20 of 22. Sign in to see all of them.
Glioblastoma (22) · Gliosarcoma (16) · Astrocytoma (9) · Brain Neoplasms (9) · Oligodendroglioma (8) · Glioma (5) · Ependymoma (3) · Neoplasms (3) · Brain Stem Neoplasms (2) · Neuroectodermal Tumors, Primitive (2) · Choroid Plexus Neoplasms (1) · Herpes Simplex (1) · Medulloblastoma (1) · Meningioma (1) · Recurrence (1)
Neoplasms by Histologic Type (22) · Neoplasms, Germ Cell and Embryonal (22) · Neoplasms, Glandular and Epithelial (22) · Neoplasms, Nerve Tissue (22) · Neoplasms, Neuroepithelial (22) · Neuroectodermal Tumors (22) · Neoplasms (19) · Glioma (17) · Astrocytoma (13) · Brain Diseases (11) · Central Nervous System Diseases (11) · Central Nervous System Neoplasms (11) · Neoplasms by Site (11) · Nervous System Diseases (11) · Nervous System Neoplasms (11)
Temozolomide (7) · Bevacizumab (3) · rindopepimut (2) · sargramostim (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Basiliximab (1) · Colony-Stimulating Factors (1) · DNA Methylation (1) · Disulfides (1) · GRN163L peptide (1) · Gene Expression Profiling (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Immunoglobulin G (1) · Immunohistochemistry (1) · Interleukin-2 (1)
National Cancer Institute (NCI) (4) · Pediatric Brain Tumor Consortium (3) · Celldex Therapeutics (2) · Celularity Incorporated (2) · Jonsson Comprehensive Cancer Center (2) · Mayo Clinic (2) · Case Comprehensive Cancer Center (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · City of Hope Medical Center (1) · Exelixis (1) · Mustafa Khasraw, MBChB, MD, FRCP, FRACP (1) · Petrov, Andrey (1) · Roswell Park Cancer Institute (1)
United States (19) · Canada (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Colombia (1) · Czechia (1) · France (1) · Georgia (1) · Germany (1) · Greece (1) · Hungary (1) · India (1) · Israel (1)
Ian Parney (2) · Behnam Badie (1) · David Peereboom, MD (1) · Dina Randazzo, DO (1) · Eric C Burton, M.D. (1) · Eudocia Q Lee (1) · Gregory Friedman, MD (1) · Kevin A Camphausen, M.D. (1) · Maryam Fouladi (1) · Phioanh Nghiemphu (1) · Robert Fenstermaker (1) · Sharmila Koppisetti, MD (1) · Stewart Goldman (1)
PMID 26670466, PMID 28844499, PMID 32009149, PMID 32034072, PMID 32154928, PMID 33571520, PMID 36346112
U01CA081457 (3), UM1CA081457 (2), P30CA016056 (1), U10CA021661 (1), U10CA180868 (1)